Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib + chemotherapy versus standard of care for first-line metastatic esophageal squamous cell carcinoma
jRCT2031210231Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, lenvatinib, cisplatin, fluorouracil, oxaliplatin and 1 more in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with adverse events and 3 more. Started Aug 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2031210231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210231.